Hormone replacement therapy after cancers

Current Opinion in Oncology

Volumn 17, Issue 5, 2005, Pages 493-499

  Creasman, William T ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Breast cancer; Endometrial cancer; Estrogen; Progestogen

Indexed keywords

ESTROGEN; PROGESTERONE; TAMOXIFEN;

BREAST CANCER; CANCER GROWTH; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CASE CONTROL STUDY; COHORT ANALYSIS; ENDOMETRIUM CANCER; ESTROGEN THERAPY; HORMONE SUBSTITUTION; HUMAN; OVARY CANCER; PRIORITY JOURNAL; REVIEW; TREATMENT CONTRAINDICATION; UTERINE CERVIX CANCER;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CLINICAL TRIALS; COHORT STUDIES; ENDOMETRIAL NEOPLASMS; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; OVARIAN NEOPLASMS;

EID: 24044546548     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000174034.62032.08     Document Type: Review

References (53)

1. Foidart JM, Colin C, Denoo X, et al. Estradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertil Steril 1998; 69:963-969.
2. Pasqualini JR, Paris J, Sitruk-Ware R, et al. Progestins and breast cancer. J Ster Biochem Molec Biol 1998; 65:225-235.
3. Desreux J, Kebers F, Noel A, et al. Effects of a progestogen on normal human breast epithelial cell apoptosis in vitro and in vivo. Breast 2003; 12:142-149.
4. Bush TL, Whiteman M, Flaws JA. Hormone replacement therapy and breast cancer: a qualitative review. Obstet Gynecol 2001 ; 98:498-508.
5. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormone Factors in Breast Cancer. Lancet 1997; 350:1047-1059.
6. Garbe E, Levesque L, Suissa S. Variability of breast cancer risk in observational studies of hormone replacement therapy: a meta-regression analysis. Maturitas 2004; 47:175-183. This study denotes the importance of the criteria used in accepting published reports for a meta-analysis review. This could change results considerably.
7. Rossouw JE, Anderson GL, Prentice RL, et al, and the Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.
8. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280:605-613.
9. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291:1701-1712. In this WHI estrogen-only study, the results note a considerable difference from the WHI estrogen-plus-progesterone study, particularly with regard to breast and heart disease.
10. Gallenberg MM, Loprinzi CL. Breast cancer and pregnancy. Semin Oncol. 1989; 16:369-376.
11. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995; 332:1589-1593.
12. Sellers TA, Mink PJ, Cerhan JR, et al. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. Ann Intern Med 1997; 127:973-980.
13. Physicians Desk Reference (PDR). 2003: p. 3447.
14. Ingle JN, Ahmann DL, Green SJ, et al. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med 1981; 304:16-21.
15. Ingle JN. Estrogen as therapy for breast cancer. Breast Cancer Res 2002; 4: 133-136.
16. Castiglione-Gertsch M, Pampallona S, Varini M, et al. Primary endocrine therapy for advanced breast cancer: to start with tamoxifen or with medroxyprogesterone acetate? Ann Oncol 1993; 4:735-740.
17. Parazzini F, Colli E, Scatigna M, Tozzi L. Treatment with tamoxifen and progestins for metastatic breast cancer in postmenopausal women: a quantitative review of published randomized clinical trials. Oncology 1993; 50:483-489.
18. Stoll BA. Hormone replacement therapy for women with past history of breast cancer. Clin Oncol 1990; 2:309-312.
19. Powles TJ, Hickish T, Case S, O'Brien M. Hormone replacement after breast cancer. Lancet 1993; 342:60-61.
20. Vassilopoulou-Sellin R, Theriault R, Klein MJ. Estrogen replacement therapy in women with prior diagnosis and treatment for breast cancer. Gynecol Oncol 1997; 65:89-93.
21. Bluming AZ, Waisman JR, Dosik GM, et al. Hormone replacement therapy (HRT) in women with previously treated primary breast cancer. Update III. Proc Am Soc Clin Oncol 1997; 16:131.
22. Brewster WR, DiSaia PJ, Grosen EA, et al. An experience with estrogen replacement therapy in breast cancer survivors. Int J Fertil Womens Med 1999; 44:186-192.
23. Natrajan PK, Soumakis K, Gambrell RD. Estrogen replacement therapy in women with previous breast cancer. Presented at the South Atlantic Association of Obstetricians and Gynecologists, White Sulfur Springs, January 24, 1999.
24. Wile AG, Opfel EW, Margilith DA. Hormone replacement therapy in previously treated breast cancer patients. Am J Surg 1993; 165:372-375.
25. Decker D, Cox T, Burdakin J, et al. Hormone replacement therapy (HRT) in breast cancer survivors (abstr). Proc Am Soc Clin Oncol 1996; 15:136.
26. Guidozzi F. Estrogen replacement therapy in breast cancer survivors. Int J Gynaecol Obstet 1999; 64:59-63.
27. Espie M, Gorins A, Peret F, et al. Hormone replacement therapy (ERT) in patients treated for breast cancer: analysis of a cohort of 120 patients [abstract]. Proc Am Soc Clin Oncol 1999; 18:586a.
28. DiSaia PJ, Grosen EA, Kurosaki T, et al. Hormone replacement therapy in breast cancer survivors: a cohort study. Am J Obstet Gynecol 1996; 174: 1494-1498.
29. Ursic-Vrscaj M, Bebar S. A case control study of hormone replacement therapy after primary surgical breast cancer treatment. Eur J Surg Oncol 1999; 25:146-151.
30. O'Meara ES, Rossing MA, Daling JR, et al. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl Cancer Inst 2001 ; 93:754-762.
31. Meurer LN, Lena S. Cancer recurrence and mortality in women using hormone replacement therapy: meta-analysis. J Fam Pract 2002; 51:1056-1062.
32. Beckmann MW, Jap D, Djahansouzi S, et al. Hormone replacement therapy after treatment of breast cancer: effect on postmenopausal symptoms, bone mineral density and recurrence rates. Oncology 2001; 60:199-206.
33. Natrajan PK, Gambrell RD. Estrogen replacement therapy in patients with early breast cancer. Am J Obstet Gynecol 2002; 187:289-294.
34. Durna EM, Wren BG, Heller GZ, et al. Hormone replacement therapy after a diagnosis of breast cancer: cancer recurrence and mortality. Med J Aust 2002; 177:347-351.
35. Dew JE, Wren BG, Eden JA. A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer. Climacteric 2003; 6: 45-52.
36. DiSaia PJ, Brewster WR, Ziogos A, Anton-Culver H. Breast cancer survival hormone replacement therapy. Am J Clin Oncol 2000; 23:541-545.
37. Decker DA, Pettinga JE, VanderVelde N, et al. Estrogen replacement therapy in breast cancer survivors: a matched-controlled series. Menopause 2003; 10:277-285.
38. Holmberg L, Anderson H. HABITS steering and data monitoring committees: HABITS (hormonal replacement therapy after breast cancer-is it safe?): a randomised comparison: trial stopped. Lancet 2004; 363:453-455. This was a prospective randomized open-label study of estrogen use after breast cancer. The increased risk of recurrence has been questioned on multiple, mainly methodologic, factors.
39. Vassilopoulou-Sellin R, Asmar L, Hortobagyi GN, et al. Estrogen replacement therapy after localized breast cancer: clinical outcome of 319 women followed prospectively. J Clin Oncol 1999; 17:1482-1487.
40. Marsden J, Whitehead M, Ahern R, et al. Are randomized trials of hormone replacement therapy in symptomatic women with breast cancer feasible? Fertil Steril 2000; 73:292-299.
41. Marttunen MB, Hietanen P, al Pyrhönenet S. A prospective study on women with a history of breast cancer and with or without estrogen replacement therapy. Maturitas 2001; 39:217-255.
42. Smith DC, Prentice R, Thompson DJ, Herrmann WL. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 1975; 293:1164-1167.
43. Persson I, Weiderpass E, Bergkvist L, et al. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Control 1999; 10:253-260.
44. Creasman WT, Henderson D, Hinshaw W, Clarke-Pearson DL. Estrogen replacement therapy in the patients treated for endometrial cancer. Obstet Gynecol 1986; 67:326-330.
45. Bryant GW. Administration of estrogen to patients with a previous diagnosis of endometrial adenocarcinoma. South Med J 1990; 83:725-726.
46. Baker DP. Estrogen-replacement therapy in patients with previous endometrial carcinoma. Compr Ther 1990; 16:28-35.
47. Lee RB, Burke TW, Park RC. Estrogen replacement therapy following treatment for stage I endometrial carcinoma. Gynecol Oncol 1990; 36:189-191.
48. Chapman JA, DiSaia PJ, Osann K, et al. Estrogen replacement in surgical stage I and II endometrial cancer survivors. Am J Obstet Gynecol 1996; 175:1195-1200.
49. Suriano KA, McHale M, McLaren CE, et al. Estrogen replacement therapy in endometrial cancer patients: a matched control study. Obstet Gynecol 2001; 97:555-560.
50. Barakat RR, Asbury R, Wadler S. A randomized double blinded trial of estrogen replacement therapy versus placebo in women with Stage I and Il endometrial adenocarcinoma [abstract]. Gynecol Oncol 2004; 92:393. In this prospective double-blind randomized study of estrogen use after endometrial cancer, the preliminary report noted no increased recurrence in those taking estrogen.
51. Coughlin SS, Giustozzi A, Smith SJ, Lee NC. A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancer. J Clin Epidemiol 2000; 53:367-375.
52. Garg PP, Kerlikowske K, Subak L, Grady D. Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis. Obstet Gynecol 1998; 92:472-479.
53. Ploch E. Hormonal replacement therapy in patients after cervical cancer treatment. Gynecol Oncol 1987; 26:169-177.